Lundbeck to delist in US

The pharmaceutical firm’s new share structure means that Lundbeck is terminating its trading program in the US.


US investors will soon be unable to trade Lundbeck shares in their own currency and during US stock exchange opening hours.

In Lundbeck’s recently publicized report for the year’s first three months, the pharmaceutical firm has announced that following a required notice period, its American Depositary Receipt (ADR) program will be terminated, meaning that trading Lundbeck shares overseas will become more difficult.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs